Oncological Outcome Prediction in Differentiated Thyroid Carcinoma: Assumption or Improved Accuracy?

Papp S , Asa SL . When thyroid carcinoma goes bad: a morphological and molecular analysis. Head Neck Pathol, 2015; 9(1):16–23; doi: 10.1007/s12105-015-0619-z.

Soares P , Póvoa AA , Melo M , et al. Molecular pathology of non-familial follicular epithelial-derived thyroid cancer in adults: From RAS/BRAF-like tumor designations to molecular risk stratification. Endocr Pathol, 2021; 32(1):44–62; doi: 10.1007/s12022-021-09666-1.

Baloch ZW , Asa SL , Barletta JA , et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol, 2022; 33(1):27–63; doi: 10.1007/s12022-022-09707-3.

Wijewardene A , Gill AJ , Gild M , et al. A retrospective cohort study with validation of predictors of differentiated thyroid cancer outcomes. Thyroid, 2022 (In Press); doi: 10.1089/thy.2021.0563.

Mete O , Rotstein L , Asa SL . Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol, 2010; 17(2):386–391; doi: 10.1245/s10434-009-0832-7.

Mete O , Asa SL , Bullock MJ , et al. The College of American Pathologists Protocol for the examination of specimens from patients with carcinomas of the thyroid gland. Version: 4.3.0.0. Protocol posting data: June 2021. Available from: www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates [Last accessed: July 1, 2022].

Mete O , Asa SL . Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol, 2011; 24(12):1545–1552; doi: 10.1038/modpathol.2011.119.

Baloch Z , Mete O , Asa SL . Immunohistochemical biomarkers in thyroid pathology. Endocr Pathol, 2018; 29(2):91–112; doi: 10.1007/s12022-018-9532-9.